Getting Food and Drug Administration approval for a new drug is usually a slam-dunk piece of good news for a company. For Savient Pharmaceuticals (Nasdaq:SVNT), though, it is only part of the story. While approval of the company's new gout treatment is absolutely a major positive development for shareholders, the ultimate fate of the company is still up in the air. (Learn about some of the most profitable drugs of all time in Stocks On Drugs: What It Takes To Get High.)
A Specialty Drug for a Rare Indication
Although gout is thought of as a disease from yesteryear, it still occurs in the Western world. For whatever reason, there is a modest percentage of gout patients who do not respond to current therapies, and Savient's drug (Krystexxa) could be a new option for them.
Please click on the link below for the complete article:
http://stocks.investopedia.com/stock-analysis/2010/Can-Savient-Soar-On-One-Specialty-Drug-SVNT-NVS-REGN-RDEA-AMGN-RHHBY-BMY0916.aspx
No comments:
Post a Comment